Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC

Shots:

• Daiichi & AstraZeneca have dosed first patient with adj. Datroway (6 mg/kg) + rilvegostomig/ rilvegostomig monotx. (750mg) in P-III (TROPION-Lung12) trial to treat stage 1a/1b adenocarcinoma NSCLC (tumors <4 cm) after complete tumor resection who are ctDNA+ or exhibit high-risk of relapse
• Study will evaluate DFS as the 1EP, while OS, safety, patient-reported physical function, plus the quality-of-life outcomes as 2EP in ~660 pts from Asia, Europe, North America and South America
• Datroway is a TROP2-directed DXd ADC discovered by Daiichi Sankyo and being co-developed and commercialized by both

Ref:  Daiichi Sankyo| Image: Daiichi Sankyo & AstraZeneca

Related News:- AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated NSCLC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com